Clozapine s side-effects put into perspective.
|
|
- Vincent Allison
- 5 years ago
- Views:
Transcription
1 Clozapine s side-effects put into perspective. Dan Cohen, psychiatrist FACT-team Heerhugowaard, The Netherlands Mental Health Organization North-Holland North, Netherlands, Europe
2 Disclosure No conflict of interests Membership of the Dutch Clozapine Collaboration Group
3 The Low- or Netherlands ( Holland ) with 17 million inhabitants FACT NHN 3
4 The special effects of clozapine: when is it time for the drug of last resort? Grant your patient an adequate trial
5 Side-effects a) Uncommon dangerous side-effects: - definition - incidence - detection - treatment b) Common & harmless, potentially dangerous side-effects: - incidence - detection - treatment
6 a. Uncommon dangerous side-effects Side-effects that are - uncommon - emerge during clozapine treatment - lethal when not timely diagnosed and adequately treated
7 How lethal are these side effects? Review of literature between Agranulocytosis - DKA - Myocarditis/cardiomyopathy Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012
8 Leukopenia and agranulocytosis 1. The first thing that comes to mind. 2. Clozapine s best studied serious side-effect. 3. This side-effect has negatively affected clozapine prescription
9 Leukopenia and agranulocytosis: the cut-off points US UK Australia Moderate leukopenia WBC 3000 WBC 3000 or ANC < 2000 WBC 3000 Severe leukopenia WBC < 2000 WBC <2000 or ANC <1000 WBC < 2000 Agranulocytosis WBC 1000 or WBC: white blood cell count ANC: absolute neutrophil count ANC 500 WBC 1000 or ANC <500 WBC 1000 or ANC 500 V. Kumar. FDA.gov
10 Differential diagnosis of leukopenia 1. Benign ethnic neutropenia (BEN) 2. Intercurrent bacterial or viral infection 3. Diurnal variation: leucocytes counts in blood shows a diurnal variation: lowest in the morning, highest in the afternoon
11 Benign Ethnic Neutropenia Definition Lower mean white blood cell (WBC) count without any signs of illness = lower WBC count in the normal, healthy population. Population People of African, Caribbean or Middle-Eastern origin
12 BEN: cut-off points WBC Neutrophils BEN Regular BEN Regular Green (=satisfactory WBC) > 3,0 x 10 9 > 3,5 x 10 9 > 1,5 x 10 9 > 2,0 x 10 9 Amber (repeat WBC) 2,5 3,0 x ,0-3,5 x ,0-1,5 x ,5-2,0 x 10 9 Red (= immediate cessation of clozapine) < 2,5 x 10 9 < 3,0 x 10 9 < 1,0 x 10 9 < 1,5 x 10 9 Rajagopal Postgrad Med J 2005
13 Intercurrent infection (Patho-)physiology Initial phase of infection Increased adherence of leucocytes to the vascular wall Leucocytes crossing the vascular wall Leucocyte migration towards the infected cell Death of leucocytes Result: lowered WBC plasma level = lowered WBC count Only later will infection result in increased production and levels of leucocytes (= leukocytosis)
14 Diurnal variation Diurnal variation: leucocytes counts in blood show diurnal variation lowest in the morning, highest in the afternoon Advise after the first leukopenia: - Rule out a mistake -> repeat WBC count from morning blood sample - Rule out diurnal variation -> WBC count from afternoon sample
15 Agranulocytosis Onset: 80-85% in the initial first 6 months Incidence Mortality Total population Affected cases 3, ,1 0,3 2,2%- 4,2% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012
16 Treatment emergent agranulocytosis: general recommendation 1. Establish a working alliance with an internist and/or hematologist before initiation of clozapine treatment, whom you can consult if necessary. 2. When leukopenia emerges, consult the internist/hematologist.
17 1.a. Other uncommon serious side-effects - Diabetic Keto-Acidosis (DKA) - Myocarditis
18 Diabetic Keto-Acidosis Rarely occurring severe disruption of the glucose homeostasis or severe worsening of pre-existing DM Cause: acute shortage of insulin Pathophysiological mechanisms are unclear
19 Diabetic Keto-Acidosis Outcome: - metabolic acidosis - metabolic ketosis - if undetected and therefore untreated: coma and death
20 Diabetic Keto-Acidosis Reported cases occurred most frequently with olanzapine or clozapine But Cases have been reported with all atypical antipsychotics
21 Diabetic Keto-Acidosis in clozapine treatment Onset seems to be restricted to the initial 3 months of treatment Diagnosis may occur later, after the hyperglycemia has become more severe and has lead to metabolic complications. Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012
22 Diabetic Keto-Acidosis in clozapine treatment Incidence Mortality Total population Affected cases 1,2-3,1 0,2-4,4 20,0%- 31,0% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012
23 Myocarditis Onset: restricted to the initial 1 month of treatment Incidence Mortality Total population Affected cases Australia 7, ,2 0%- 13% Rest of world 0,07 0,6 0-0,2 0%- 68%
24 b. Common & harmless: the case of constipation Constipation occurs in 25,1% of clozapine-treated patients. Danger: severe constipation can result in (sub-)ileus and eventually death. Meltzer InterSept Trial. Arch Gen Psychiatry 2003
25 Risk factors of GIH 1. Co-medication: anticholinergic drugs or other drugs that cause constipation. Caveat: medication is only co-medication from a psychiatric point of view, not from that of the GP or somatic specialist. 2. Dosage: more risk with higher dosage 3. Treatment duration: conflicting results. initial phase: 36% < 4 months, 50% < 1 year (Palmer) maintenance phase: mean duration 1528 days (Nielsen) Palmer J Clin Psych 2008; Nielssen & Meyer Schizophr Bull 2011
26 GIH: (sub-)ileus Incidence Mortality Total population Affected cases 4-8 0,98 1,19 15,0%- 27,5%
27 Comparison of incidence ( ) & mortality rates of all 4 dangerous side effects of clozapine. Incidence Mortality Total population ( ) Total population ( ) Incident cases Agranulocytosis 3,8 8,0 0,1-0,3 2,2-4,2% DKA 1,2-3,1 0,2-4,4 20,0-31,0% GIH 4,0-8,0 0,98-1,19 15,0-27,5 % Myocarditis: Australia 7,0 34,0 0-1,2 0-13% Rest of the world 0,07-0,6 0-0,2 0-68% Cohen, Bogers, van Dijk, Bakker, Schulte. J Clin Psychiatry 2012
28 Uncommon serious side-effects: agranulocytosis In general, psychiatrists are excessively worried over the chances and risks of agranulocytosis. They tend to be less worried about - some even unaware of other serious side effects. Both positions are wrong.
29 Incidence and mortality of agranulocytosis put into perspective Incidence Country Study pop Agranulocytosis Incidence USA N= cases 0.382% Australia N= cases 0.3% In the US-study, 12 patients died. Honigfeld J Clin Psych 1998; Drews Australasian Psych 2013
30 Incidence and mortality of agranulocytosis put into perspective Mortality rate - Affected population(12/382) = 3,14% - Total population (12/99.500) = 0,1 (= 1: patients) Honigfeld J Clin Psych 1998
31 Uncommon serious side-effects: incidence and mortality of agranulocytosis put into perspective Conclusion Within the framework of mandatory WBC monitoring, the risk of agranulocytosis is low and kept within acceptable borders.
32 Uncommon serious side-effects: agranulocytosis incidence and mortality in perspective Obligatory WBC-count has shown to be effective in preventing death as complications of agranulocytosis. What about the other 3 serious side-effects?
33 Screening advise for DKA, GIH and myocarditis Aim Reduction of the current high mortality rates to that of agranulocytosis
34 Screening advise DKA Baseline measurement of fasting plasma glucose (FPG) Monthly FPG measurement during the months at risk = the first 3 months of clozapine treatment Thereafter: yearly measurement of FPG
35 Screening advise DKA: the role of HbA1c HbA1c is a reliable predictor of long term DM complications reflects mean plasma glucose of the previous 2 months is therefore unsuitable for detection of rapidly developing new-onset DM and DKA
36 Screening advise GIH: two options and one obligation: Two options Option 1. Patients defecation pattern is a standard topic at every visit. Option 2. Patients defecation pattern is a standard topic at every visit and preventive prescription of macrocol laxative in all clozapine patients.
37 Screening advise GIH: two options and one obligation: Obligation Warn and inform the GP on - the risk of GIH as a side-effect of clozapine - the possibility of additional risk of constipation due to constipating effect of somatic (co-)medication.
38 Screening advise myocarditis 1. For reasons unknown, myocarditis in clozapine treatment is mainly a problem of Australia and New-Zealand. 2. There is no evidence that warrants routinely monitoring of treatment emergent myocarditis outside Australia and New- Zealand.
39 The special effect of clozapine: what is the right moment for prescription of this drug of last resort? Grant your patients a safe treatment with clozapine!
40 Thank you for your attention!
41 Questions?
Separating chaff from the wheat. Evidence-based obligatory screening of sideeffects in clozapine treatment.
Separating chaff from the wheat. Evidence-based obligatory screening of sideeffects in clozapine treatment. Dan Cohen, psychiatrist FACT-team Heerhugowaard North-Holland North, Netherlands, Europe Disclosure
More informationAgranulocytosis in clozapine: myths and facts
Agranulocytosis in clozapine: myths and facts Dr. P.F.J. Schulte, psychiatrist Mental Health Services Noord-Holland-Noord Alkmaar, Netherlands Statement of Potential Conflicts of Interest Agranulocytosis
More informationLadies and gentlemen, good afternoon! Let me talk to you about myths and facts of clozapine. Of course you are all aware of the fact that clozapine
Ladies and gentlemen, good afternoon! Let me talk to you about myths and facts of clozapine. Of course you are all aware of the fact that clozapine has unique efficacy in therapy refractory schizophrenia,
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationClozapine, neutropenia and agranulocytosis, red alert management
Clozapine, neutropenia and agranulocytosis, red alert management The information in this document is not intended as a definitive treatment strategy, but as a suggested approach for clinicians. It is based
More informationFirst Steps: Considering Clozapine for your Patients
First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationFor personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Copyright Dowden Health Media For personal use only Clozapine, despite its side effect burden, may be the most effective
More informationTitrating Clozapine amidst Recommendations Proposing High Myocarditis Risk and Rapid Titrations
University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 10-2015 Titrating Clozapine amidst Recommendations Proposing High Myocarditis Risk and Rapid Titrations Jose de Leon University
More informationSevere Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug
Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Severe Diabetic Ketoacidosis Precipitated by an Atypical Antipsychotic Drug Mohammad Naeem Niazy, MRCP, FRCPI* Ghassan Baidas, MRCP, FRCPI* Thomas
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationHave you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider.
Have you already tried different drugs for your schizophrenia? Here s another option you and your doctor may want to consider. 1 Benefits of Clozapine Clozapine may work when other medications don t. Doctors
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationClozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report
CASE REPORT Clozapine and Polycythemia Rubra Vera: A Rare Side Effect or a Separate Medical Condition? A Case Report Tan HPJ Hospital Sentosa, Kuching, Sarawak, Malaysia Abstract This article highlights
More informationGuideline for the In-patient initiation of Clozaril (Clozapine) within CWPT
Guideline for the In-patient initiation of Clozaril (Clozapine) within CWPT Version: 1 Author: Ambreena Asghar Designation: Pharmacist Responsible Director: Sharon Binyon Approved By: Drugs and Therapeutics
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationClozapine is an atypical antipsychotic agent with
CASE REPORT Continuing Clozapine Therapy Despite Morning Pseudoneutropenia Sean P Spina and Susan P Corrigan INTRODUCTION Clozapine is an atypical antipsychotic agent with demonstrated effectiveness for
More informationThe licensed indications for the use of Clozapine are:- Treatment resistant schizophrenia.
1. Introduction Future Directions CIC will support the use of the antipsychotic Clozapine in all appropriate cases. The purpose of this procedure is to set out the standards for Clinicians, Pharmacists,
More informationDosing and administration information for ABILIFY MAINTENA (aripiprazole)
DOSING AND ADMINISTRATION GUIDE Dosing and administration information for ABILIFY MAINTENA (aripiprazole) Approved for deltoid or gluteal administration ABILIFY MAINTENA (aripiprazole) is an atypical antipsychotic
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD
Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,
More informationClozapine Underutilization: Addressing the Barriers
Clozapine Underutilization: Addressing the Barriers Deanna L. Kelly, Pharm.D., BCPP Professor of Psychiatry Director, Treatment Research Program Maryland Psychiatric Research Center University of Maryland
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine INPATIENT INITIATION
Document Reference MM 048 Integrated Care Pathway (ICP) for the Management of clozapine INPATIENT INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationESSENTIAL SHARED CAR E AGREEMENT FOR
E093 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in People with Learning Disability (LD) Referral Criteria In some
More informationBeyond clozapine: a review of the literature on clozapine resistance
Beyond clozapine: a review of the literature on clozapine resistance Jan Bogers j.bogers@ggzleiden.nl www.clozapinepluswerkgroep.nl Dutch Clozapine Collaboration Group Mental Health Services Rivierduinen
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationUNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western
UNDERSTANDING AND MANAGING METABOLIC SYNDROME IN PSYCHIATRY Dr Sanil Rege MBBS, MRCPsych, FRANZCP Consultation-Liaison Psychiatry PaRK MHS, Western Australia Talks Facilitator of the CTF Exam Prep Course
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationParticipating Hospital Certification Form
Participating Hospital Certification Form ATTENTION: this Certification Form is only applicable for Free Trial Product Units of ABILIFY MAINTENA (aripiprazole). Instructions: The Authorized Representative
More informationNCDPS Health Services Elissa Brody, CNM, BSN, RN Education Director June 2017
NCDPS Health Services Elissa Brody, CNM, BSN, RN Education Director June 2017 Disclosure NC Department of Public Safety Division of Adult Corrections/Prisons Health Services- Nursing Education NCNA Approved
More informationFDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia
FOR IMMEDIATE RELEASE FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extendedrelease injectable suspension in the Treatment of Schizophrenia Patients being treated for schizophrenia
More informationADMINISTRA TIVE/FISCAL/CLINICAUPHF POLICY AND PROCEDURES
ADMINISTRA TIVE/FISCAL/CLINICAUPHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1 /09 Policy- #56 CLOZAPINE PRESCRIBING
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationPhysical Health Management: Why it s important for adolescents and young adults in mental health services
Physical Health Management: Why it s important for adolescents and young adults in mental health services Early Intervention Service Wellington Lauren Heath and Erin Dawson Introduction Second generation
More informationLAIs and the Challenge of Medication Non-Adherence The Care Transitions Network
LAIs and the Challenge of Medication Non-Adherence The Care Transitions Network Lauren Hanna, M.D. The Zucker Hillside Hospital Northwell Health National Council for Behavioral Health Montefiore Medical
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationMore than We Bargained For: Metabolic Side Effects of Antipsychotic Medications
More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationDIABETES MELLITUS. IAP UG Teaching slides
DIABETES MELLITUS 1 DIABETES MELLITUS IN CHILDREN Introduction, Definition Classification, pathogenesis Clinical features Investigations and diagnosis Therapy and follow up Complications Carry home message
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationClaire Thomas, Deputy Chief Pharmacist. Tim Donaldson, Trust Chief Pharmacist. Contents. Section Description Page No.
Pharmacological Therapy Policy Practice Guidance Note Safe Prescribing of Clozapine V02 Version issued Issue 1 Jan 16 Issue 2 Nov 16 Planned review January 2019 PPT-PGN-05 Part of NTW(C)38 Pharmacological
More informationCLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent.
CLOZAPINE Introduction Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent. Due to its potential for significant toxicity, it is reserved for patients
More informationNorth Central London Medicines Optimisation Committee
North Central London Medicines Optimisation Committee Guidance for Pharmacy Staff Managing Clozapine For Patients Admitted to Acute Hospitals Disclaimer This guideline is registered at North Central London
More informationDementia and Diabetes
Dementia and Diabetes Dr Jill Rasmussen RCGP Clinical Representative Dementia, jill.rasmussen@psi-napse.com 1 Dementia and Diabetes - Overview The Facts Implications for the Well Pathway Mild Cognitive
More informationMulticellular Organisms
Multicellular Organisms Sub-Topic (2.2) Control and Communication Hormonal Control (b) On completion of this sub-topic I will be able to state that: Hormones are chemical messengers Hormones are released
More informationFirst Episode Schizophrenia
First Episode Schizophrenia Abigail Donovan, M.D. Assistant Professor of Psychiatry, Harvard Medical School Director, First Episode and Early Psychosis Program MGH Schizophrenia Program Massachusetts General
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationBOXED WARNING 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE
BOXED WARNING 1. AGRANULOCYTOSIS BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR USE IN (1) THE TREATMENT OF SEVERELY ILL
More informationDiabetes Mellitus in the Pediatric Patient
Diabetes Mellitus in the Pediatric Patient William Bryant, M.D. Chief of Section Pediatric Endocrinology Children s Hospital at Scott & White Texas A&M University Temple, Texas Disclosures None Definitions
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
More informationIntegrated Care Pathway (ICP) for the. Management of clozapine COMMUNITY INITIATION
Document Reference MM 049 Integrated Care Pathway (ICP) for the Management of clozapine COMMUNITY INITIATION Surname Title Address Forenames Date of Birth RT/NHS number Care Co-ordinator GP CS number Consultant
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationObjectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia
Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationClozapine-induced concordant agranulocytosis
Ó 2001 Martin Dunitz Ltd International Journal of Psychiatry in Clinical Practice 2001 Volume 5 Pages 71 ± 73 71 Clozapine-induced concordant agranulocytosis in monozygotic twins J HORAÂ C Ï EK, J LIBIGER,
More informationDoubled risk of Depression in Diabetes Prevalence: 10-20%
Bright Light Treatment for better Mood and Metabolic control: a Randomised Controlled Trial in patients with Type-2- Diabetes and Major Depressive Disorder Project group: Annelies Brouwer, PhD-student
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION CLOZAPINE TABLETS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CLOZAPINE TABLETS safely and effectively. See full prescribing information for CLOZAPINE TABLETS.
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationVERSACLOZ (clozapine) oral suspension Initial U.S. Approval: 1989
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VERSACLOZ safely and effectively. See full prescribing information for VERSACLOZ. VERSACLOZ (clozapine)
More informationPRODUCT MONOGRAPH. CLOZARIL (Clozapine Tablets) 25 mg and 100 mg
PRODUCT MONOGRAPH Pr CLOZARIL (Clozapine Tablets) 25 mg and 100 mg Antipsychotic Agent HLS Therapeutics Inc. 10 Carlson Court, Suite 410 Etobicoke, Ontario M9W 6L2 Control No.: 205552 CLOZARIL is a registered
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More informationCLOZARIL (clozapine) tablets, for oral use. Initial U.S. Approval: 1989
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CLOZARIL safely and effectively. See full prescribing information for CLOZARIL. CLOZARIL (clozapine)
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationGENERAL PRACTITIONER (GP) SUPPORT PACK
Document Reference MM 050 Integrated Care Pathway (ICP) for the Management of clozapine GENERAL PRACTITIONER (GP) SUPPORT PACK One pack to be printed for each patient initiated on clozapine treatment,
More informationPharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015
Pharmacological Managment of Treatment Resistant Schizophrenia Jean-Marie Batail - France 21 st July 2015 Introduction A chronic and debilitating illness - Lifetime prevalence of around 0,7%. - Beginning
More informationUniversity of Groningen
University of Groningen A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole Schorr, S. G.; Slooff, C. J.; Postema, R.; Van Oven, W.; Schilthuis, M.; Bruggeman, Richard;
More information5/12/2011. Recognize the major types of diabetes: Type 2, Type 1A, Type 1B, MODY, LADA, Pancreatic diabetes, drug-induced DM
J. Christopher Lynch, Pharm.D. Professor Acting Associate Dean of Student Affairs Southern Illinois University Edwardsville School of Pharmacy The speaker has no conflicts of interest to disclose Recognize
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationClozapine Shared Care Protocol And Information For Oxfordshire GPs
Clozapine Shared Care Protocol And Information For Oxfordshire GPs There should be willing consent of all parties to enter into a shared care agreement. This includes patients (plus carers if necessary)
More informationPRODUCT MONOGRAPH. Clozapine Tablets. 25 mg, 50 mg, 100 mg and 200 mg. Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension.
PRODUCT MONOGRAPH Pr GEN-CLOZAPINE Clozapine Tablets 25 mg, 50 mg, 100 mg and 200 mg Pharmaceutical Standard: Mylan Std. Clozapine Oral Suspension 50 mg/ml Antipsychotic Agent Mylan Pharmaceuticals ULC
More informationCLOZAPINE TREATMENT GUIDELINES MARCH 2017
CLOZAPINE TREATMENT GUIDELINES MARCH 2017 0 Policy title Clozapine treatment guidelines Policy PHA06 reference Policy category All clinical staff who deal with medication in the Trust. Relevant to Clinical
More informationClozapine associated diabetic acidosis
www.edoriumjournals.com Letter To Editor open ACCESS Clozapine associated diabetic acidosis Kalliopi Kotsa, Evangelos Potolidis, Vasiliki Lygoura, Charalampos Mandros, Panagiotis Fanourgiakis ABSTRACT
More informationUrgent Medical Device Correction
Urgent Medical Device Correction Contact TM Detach Infusion Sets: Needle May Fracture From the Connect/Disconnect Location August 10, 2015 Dear Valued Customer: Unomedical a/s, a ConvaTec Company has initiated
More informationNow it s time for... Teva Clozapine. (Clozapine, USP Tablets and Orally Disintegrating Tablets) Patient & Family Guide to Teva Clozapine Therapy
Now it s time for... Teva Clozapine (Clozapine, USP Tablets and Orally Disintegrating Tablets) Patient & Family Guide to Teva Clozapine Therapy This is a very important time in your life You and your family
More informationUse of Psychotherapeutic Medications in Children and Adolescents with ASD and ID
Use of Psychotherapeutic Medications in Children and Adolescents with ASD and ID Although not considered first line treatment in children with ASD and ID, depending on the severity of symptoms, some medications
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode
updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug
More informationAlameda County Behavioral Health Care Services
I. Background A. General Information Clozapine is an antipsychotic that is FDA approved for treatment-refractory schizophrenia and reduction of recurrent suicidal behavior in schizophrenia or schizoaffective
More informationAge / Sex: 31-year-old bi-racial male admitted to hospital through. Background:
Stephen M. Goldfinger, MD Chart Review: The Patient You Hate to Treat PATIENT INFO 31 / Male Age / Sex: 31-year-old bi-racial male admitted to hospital through Background: Psychiatric Emergency Services.
More informationWith Dr. Sarah Reid and Dr. Sarah Curtis
5. Headaches 6. Known diabetes 7. Specific high risk groups (ie. Teenagers, children on insulin pumps and those from lower socio-economic status). Episode 63 Pediatric Diabetic Ketoacidosis With Dr. Sarah
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationYou wrote ZYPREXA. Will your patient leave the pharmacy with something else? (cetirizine HCl) have been mistaken, one for the other, in the past.
ZYPREXA (olanzapine)? You wrote ZYPREXA. Will your patient leave the pharmacy with something else? With over 4,000 drugs on the market and more than 8 million prescriptions filled every day, medication
More informationAiming for recovery for patients with severe or persistent depression a view from secondary care. Chrisvan Koen
Aiming for recovery for patients with severe or persistent depression a view from secondary care Chrisvan Koen Kent and Medway NHS and Social care Partnership trust Persistent depressive disorder F34 Persistent
More informationDiabetes distress 7 A s model
Diabetes and emotional health: A toolkit for health s supporting adults with type 1 or type 2 diabetes Diabetes distress 7 A s model AWARE Be AWARE that people with diabetes may experience diabetes distress
More informationIntegrating Behavioral Health into Primary Care: Collaborative-Care Models
Integrating Behavioral Health into Primary Care: Collaborative-Care Models Presented at the National Health Policy Forum September 17 th, 2013 Marc Avery, MD Clinical Associate Professor Associate Director
More informationDiabetes Mellitus and the Dental Healthcare Professional
Diabetes Mellitus and the Dental Healthcare Professional Jerry A. Brown DMD, CDE University of South Florida Department of Internal Medicine jabrown7@health.usf.edu Learning Objectives Diabetes- The Disease
More informationDiabetes. Ref HSCW 024
Diabetes Ref HSCW 024 Why is it important? Diabetes is an increasingly common, life-long, progressive but largely preventable health condition affecting children and adults, causing a heavy burden on health
More informationTalking to Patients and Their Families
Talking to Patients and Their Families About Clozapine The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationCLOZAPINE. Generic? Yes
CLOZAPINE THERAPEUTICS Brands Clozaril Leponex Versacloz (oral suspension) Fazaclo ODT (oral disintegrating tablet) see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature:
More informationNHS GG&C Introduction of Freestyle Libre flash glucose monitoring system
NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system The Freestyle Libre flash glucose monitoring system is a sensor based, factory-calibrated system that measures interstitial fluid
More information